Effects of Bezafibrate on Lipid and glucose metabolism in dyslipidemic patients with impaired glucose tolerance - Comparative analysis of the characteristics of dyslipidemia improving drugs for postprandial metabolic disorder.
Phase 4
- Conditions
- Patients with metabolic syndrome
- Registration Number
- JPRN-UMIN000008157
- Lead Sponsor
- Department of Cardiovascular Medicine, Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have contraindication of bezafibrate or atrovastatin treatment. 2) Patients who have taken any lipid-lowering drug within one month. 3) Patient who have taken any antidaibetic agents. 4) Alcoholic patients. 5) Patients judged to be unsuitable participants by physician-in-charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Levels of triglycerides, HDL-cholesterol, total cholesterol and LDL-cholesterol 2) Diameter of lipoproteins measured by HPLC 3)HbA1c (NGSP) and 75g OGTT (glucose and insulin levels at 0, 30, 60 and 120 min after glucose load) 4)Safety (Adverse effects including hypoglycemia, body weigh gain)
- Secondary Outcome Measures
Name Time Method 1)MDA-LDL levels and MDA-LDL/LDL cholesterol 2)Insulin sensitivity (HOMA-IR, QUICKI) 3)Plasma adiponectin levels 4)Plasma high sensitive C reactive protein levels 5)Body weight, body mass index (BMI) and blood pressure 6)Renal function and liver function tests